$ELDN
Eledon Pharmaceuticals, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024098590 Filed on August 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.990M $4.396M
YoY Change 22.02% 39.42%
% of Gross Profit
Research & Development $16.52M $10.11M
YoY Change 108.3% 40.34%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $20.51M $14.50M
YoY Change 83.16% 40.06%
Operating Profit -$20.51M -$14.50M
YoY Change 83.16% 40.06%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.042M $869.0K
YoY Change 22.73% 12.13%
Pretax Income $76.97M -$44.91M
YoY Change -843.68% 368.81%
Income Tax
% Of Pretax Income
Net Earnings $77.00M -$44.91M
YoY Change -844.03% 368.81%
Net Earnings / Revenue
Basic Earnings Per Share $1.05 -$1.06
Diluted Earnings Per Share -$0.32 -$1.06
COMMON SHARES
Basic Shares Outstanding 39.66M 38.51M
Diluted Shares Outstanding 55.48M 42.28M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $78.19M $83.61M
YoY Change 31.19% 17.14%
Cash & Equivalents $6.751M $26.04M
Short-Term Investments $71.44M $57.57M
Other Short-Term Assets $442.0K $157.0K
YoY Change 391.11% -34.03%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $81.51M $87.22M
YoY Change 29.4% 18.47%
LONG-TERM ASSETS
Property, Plant & Equipment $471.0K $621.0K
YoY Change -5.8% 12.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $210.0K $255.0K
YoY Change -9.87% 13.84%
Total Long-Term Assets $33.07M $33.26M
YoY Change -0.03% 0.3%
TOTAL ASSETS
Total Short-Term Assets $81.51M $87.22M
Total Long-Term Assets $33.07M $33.26M
Total Assets $114.6M $120.5M
YoY Change 19.26% 12.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.860M $2.148M
YoY Change 1160.22% -2.23%
Accrued Expenses $6.629M $3.877M
YoY Change 176.21% 43.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.49M $6.025M
YoY Change 330.8% 22.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $24.28M $121.2M
YoY Change 24177.0% 65773.37%
Total Long-Term Liabilities $24.28M $121.2M
YoY Change 24177.0% 65773.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.49M $6.025M
Total Long-Term Liabilities $24.28M $121.2M
Total Liabilities $38.52M $129.0M
YoY Change 713.65% 1786.83%
SHAREHOLDERS EQUITY
Retained Earnings -$311.0M -$387.9M
YoY Change 33.13% 73.79%
Common Stock $386.9M $379.4M
YoY Change 19.09% 17.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $76.06M -$8.501M
YoY Change
Total Liabilities & Shareholders Equity $114.6M $120.5M
YoY Change 19.26% 12.83%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $77.00M -$44.91M
YoY Change -844.03% 368.81%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$11.77M -$7.774M
YoY Change -3.93% -5.44%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$12.80M -$19.91M
YoY Change -48.85% -34.35%
Cash From Investing Activities -$12.80M -$19.91M
YoY Change -48.85% -34.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.283M 48.07M
YoY Change 45.59%
NET CHANGE
Cash From Operating Activities -11.77M -7.774M
Cash From Investing Activities -12.80M -19.91M
Cash From Financing Activities 5.283M 48.07M
Net Change In Cash -19.29M 20.38M
YoY Change -48.26% -468.08%
FREE CASH FLOW
Cash From Operating Activities -$11.77M -$7.774M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
46490000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5027000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
87221000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
56129000
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001404281
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36620
dei Entity Registrant Name
EntityRegistrantName
ELEDON PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1000967
dei Entity Address Address Line1
EntityAddressAddressLine1
19800 MacArthur Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92612
dei City Area Code
CityAreaCode
(949)
dei Local Phone Number
LocalPhoneNumber
238-8090
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
ELDN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39655702
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26039000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4612000
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
57571000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
46490000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3611000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5027000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
87221000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
56129000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
621000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
365000
CY2024Q2 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2023Q4 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
255000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
186000
CY2024Q2 us-gaap Assets
Assets
120483000
CY2023Q4 us-gaap Assets
Assets
89066000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2148000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
967000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
269000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
383000
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3608000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2545000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6025000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3895000
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1752000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1752000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
386000
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
120821000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
76211000
CY2024Q2 us-gaap Liabilities
Liabilities
128984000
CY2023Q4 us-gaap Liabilities
Liabilities
81858000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
621000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
365000
CY2024Q2 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2023Q4 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
255000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
186000
CY2023Q4 us-gaap Assets
Assets
89066000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
967000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
269000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
383000
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3608000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2545000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6025000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3895000
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1752000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1752000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
386000
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
120821000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
76211000
CY2024Q2 us-gaap Liabilities
Liabilities
128984000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38506614
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38506614
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24213130
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24213130
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
39000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
24000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
379400000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
326586000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-387940000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-319402000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-8501000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7208000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
120483000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89066000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10106000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7201000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17516000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15314000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38506614
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38506614
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24213130
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24213130
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
24000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
379400000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
326586000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-387940000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-319402000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-8501000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7208000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
120483000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89066000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10106000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7201000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17516000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15314000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4396000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3153000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6150000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
14502000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
10354000
us-gaap Operating Expenses
OperatingExpenses
25371000
us-gaap Operating Expenses
OperatingExpenses
21464000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14502000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10354000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25371000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21464000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
869000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
775000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1443000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1113000
CY2024Q2 eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
31274000
CY2023Q2 eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
56181000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
44610000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
56181000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-44907000
us-gaap Net Income Loss
NetIncomeLoss
-68538000
us-gaap Net Income Loss
NetIncomeLoss
-76532000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.74
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4396000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3153000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7855000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6150000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
14502000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
10354000
us-gaap Operating Expenses
OperatingExpenses
25371000
us-gaap Operating Expenses
OperatingExpenses
21464000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14502000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10354000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25371000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21464000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
869000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
775000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1113000
CY2024Q2 eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
31274000
CY2023Q2 eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
56181000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
44610000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
56181000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-44907000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65760000
us-gaap Net Income Loss
NetIncomeLoss
-68538000
us-gaap Net Income Loss
NetIncomeLoss
-76532000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.74
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.9
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.9
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.99
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42278411
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42278411
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24006549
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24006549
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36133906
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36133906
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19173080
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19173080
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7208000
CY2024Q1 eldn Issuance Of Common Stock In Connection With Exercise Of Pre Funded Warrants Value
IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue
1000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1694000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-23631000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-14728000
CY2024Q2 eldn Issuance Of Common Stock In Connection With Private Investment In Public Equity Transaction Net Of Issuance Costs Value
IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue
48070000
CY2024Q2 eldn Issuance Of Common Stock In Connection With Exercise Of Pre Funded Warrants Value
IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue
1000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3063000
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.9
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.9
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.99
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42278411
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42278411
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24006549
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24006549
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36133906
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36133906
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19173080
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19173080
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7208000
CY2024Q1 eldn Issuance Of Common Stock In Connection With Exercise Of Pre Funded Warrants Value
IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue
1000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1694000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-23631000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-14728000
CY2024Q2 eldn Issuance Of Common Stock In Connection With Private Investment In Public Equity Transaction Net Of Issuance Costs Value
IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue
48070000
CY2024Q2 eldn Issuance Of Common Stock In Connection With Exercise Of Pre Funded Warrants Value
IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue
1000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3063000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-44907000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-8501000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
84183000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1381000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10772000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
74792000
CY2023Q2 eldn Issuance Of Common Stock In Connection With Private Investment In Public Equity Transaction Net Of Issuance Costs Value
IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue
33017000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1720000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
43768000
us-gaap Net Income Loss
NetIncomeLoss
-68538000
us-gaap Net Income Loss
NetIncomeLoss
-76532000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
10000
eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
192000
eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
186000
eldn Accretion On Investment Discounts
AccretionOnInvestmentDiscounts
-951000
eldn Accretion On Investment Discounts
AccretionOnInvestmentDiscounts
-97000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4757000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3101000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
44610000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
56181000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1347000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-791000
eldn Accounts Payable Accrued Expenses And Other Liabilities
AccountsPayableAccruedExpensesAndOtherLiabilities
2244000
eldn Accounts Payable Accrued Expenses And Other Liabilities
AccountsPayableAccruedExpensesAndOtherLiabilities
-1603000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-166000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-172000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-44907000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-8501000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1381000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10772000
CY2023Q2 eldn Issuance Of Common Stock In Connection With Private Investment In Public Equity Transaction Net Of Issuance Costs Value
IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue
33017000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1720000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65760000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
43768000
us-gaap Net Income Loss
NetIncomeLoss
-68538000
us-gaap Net Income Loss
NetIncomeLoss
-76532000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
10000
eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
192000
eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
186000
eldn Accretion On Investment Discounts
AccretionOnInvestmentDiscounts
-951000
eldn Accretion On Investment Discounts
AccretionOnInvestmentDiscounts
-97000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4757000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3101000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
56181000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1347000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-791000
eldn Accounts Payable Accrued Expenses And Other Liabilities
AccountsPayableAccruedExpensesAndOtherLiabilities
2244000
eldn Accounts Payable Accrued Expenses And Other Liabilities
AccountsPayableAccruedExpensesAndOtherLiabilities
-1603000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-166000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-172000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16515000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18145000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
49230000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
30334000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
39100000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10130000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30334000
eldn Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet
48072000
eldn Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet
33017000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48072000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33017000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21427000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15462000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4612000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56409000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26039000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40947000
eldn Common Stock Exchanged For X And X One Non Voting Convertible Preferred Stock
CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock
1000
eldn Increase Decrease In Operating Lease Asset And Liability Due To New Lease
IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToNewLease
448000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16515000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18145000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
49230000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
30334000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
39100000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10130000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30334000
eldn Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet
48072000
eldn Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet
33017000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48072000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33017000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21427000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15462000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4612000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56409000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26039000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40947000
eldn Common Stock Exchanged For X And X One Non Voting Convertible Preferred Stock
CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock
1000
eldn Increase Decrease In Operating Lease Asset And Liability Due To New Lease
IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToNewLease
448000
us-gaap Net Income Loss
NetIncomeLoss
-68500000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16500000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-387900000
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
83600000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-387900000
eldn Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
three months or less
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to stock-based compensation expense, warrant liabilities, the fair value of right-of-use assets and liabilities, accruals for liabilities, impairment of long-lived assets, and other matters that affect the consolidated financial statements and related disclosures. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consists of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured institutions in excess of federally insured limits and invests in short-term investments with the primary objective of seeking to preserve principal, achieve liquidity requirements and safeguard invested funds. We believe that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held and the nature, including the credit ratings, of our cash equivalents and short-term investments, but we have not eliminated all credit risk.</span></p>
eldn Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
three months or less
eldn Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
three months or less
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
57571000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
57571000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
46490000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
46490000
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
57571000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
57571000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
46490000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
46490000
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
57571000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
57571000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
46490000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
46490000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
44600000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
44600000
CY2024Q2 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
2907000
CY2023Q4 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
4128000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
260000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
624000
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
287000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
185000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
157000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
90000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3611000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5027000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
44600000
CY2024Q2 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
2907000
CY2023Q4 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
4128000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
260000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
624000
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
287000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
185000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
157000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
90000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3611000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5027000
CY2024Q2 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
2907000
CY2023Q4 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
4128000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
260000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
624000
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
287000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
185000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
157000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
90000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3611000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5027000
CY2024Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1561000
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2003000
CY2024Q2 eldn Accrued Clinical Current
AccruedClinicalCurrent
1248000
CY2023Q4 eldn Accrued Clinical Current
AccruedClinicalCurrent
451000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
94000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
44000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2545000
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2024Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1561000
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2003000
CY2024Q2 eldn Accrued Clinical Current
AccruedClinicalCurrent
1248000
CY2023Q4 eldn Accrued Clinical Current
AccruedClinicalCurrent
451000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
94000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
705000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2545000
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
eldn Lessee Operating Lease Remaining Term Of Contract
LesseeOperatingLeaseRemainingTermOfContract
P3Y
CY2024Q2 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
us-gaap Operating Lease Cost
OperatingLeaseCost
203000
us-gaap Operating Lease Cost
OperatingLeaseCost
199000
CY2024Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1561000
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2003000
CY2024Q2 eldn Accrued Clinical Current
AccruedClinicalCurrent
1248000
CY2023Q4 eldn Accrued Clinical Current
AccruedClinicalCurrent
451000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
94000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
47000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
705000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
44000
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3608000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2545000
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
eldn Lessee Operating Lease Remaining Term Of Contract
LesseeOperatingLeaseRemainingTermOfContract
P3Y
CY2024Q2 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
us-gaap Operating Lease Cost
OperatingLeaseCost
203000
us-gaap Operating Lease Cost
OperatingLeaseCost
199000
us-gaap Operating Lease Payments
OperatingLeasePayments
114000
us-gaap Operating Lease Payments
OperatingLeasePayments
181000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
eldn Lessee Operating Lease Remaining Term Of Contract
LesseeOperatingLeaseRemainingTermOfContract
P3Y
CY2024Q2 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
us-gaap Operating Lease Cost
OperatingLeaseCost
203000
us-gaap Operating Lease Cost
OperatingLeaseCost
199000
us-gaap Operating Lease Payments
OperatingLeasePayments
114000
us-gaap Operating Lease Payments
OperatingLeasePayments
181000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M1D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y5M12D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0212
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0249
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
185000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
191000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
197000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
100000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
673000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
18000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
655000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
269000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
386000
us-gaap Operating Lease Payments
OperatingLeasePayments
114000
us-gaap Operating Lease Payments
OperatingLeasePayments
181000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M1D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y5M12D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0212
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0249
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
185000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
191000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
197000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
100000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
673000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
18000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
655000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
269000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
386000
CY2024Q2 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0433
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0384
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M1D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y5M12D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0212
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0249
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
185000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
191000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
197000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
100000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
673000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
18000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
655000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
269000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
386000
CY2024Q2 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0433
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0384
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0388
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.919
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9715
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8908
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9428
CY2024Q2 us-gaap Share Price
SharePrice
2.64
CY2023Q4 us-gaap Share Price
SharePrice
1.8
CY2024Q2 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0433
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0384
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0388
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.919
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9715
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8908
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9428
CY2024Q2 us-gaap Share Price
SharePrice
2.64
CY2023Q4 us-gaap Share Price
SharePrice
1.8
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3063000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1720000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4757000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3101000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0388
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.919
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9715
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8908
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9428
CY2024Q2 us-gaap Share Price
SharePrice
2.64
CY2023Q4 us-gaap Share Price
SharePrice
1.8
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3063000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1720000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4757000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3101000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-44907000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65760000
us-gaap Net Income Loss
NetIncomeLoss
-68538000
us-gaap Net Income Loss
NetIncomeLoss
-76532000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.9
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.9
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.99
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42278411
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42278411
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24006549
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3063000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1720000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4757000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3101000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-44907000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65760000
us-gaap Net Income Loss
NetIncomeLoss
-68538000
us-gaap Net Income Loss
NetIncomeLoss
-76532000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.74
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.9
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.9
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.99
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42278411
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42278411
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24006549
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24006549
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36133906
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36133906
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19173080
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19173080
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-44907000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65760000
us-gaap Net Income Loss
NetIncomeLoss
-68538000
us-gaap Net Income Loss
NetIncomeLoss
-76532000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.74
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.9
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.9
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.99
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42278411
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42278411
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24006549
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24006549
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36133906
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36133906
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19173080
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19173080
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33791508
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25263692
CY2023Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
56181000
CY2023Q2 us-gaap Liabilities
Liabilities
63017000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
23000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
323142000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-279397000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24006549
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36133906
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36133906
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19173080
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19173080
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33791508
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25263692
CY2023Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
56181000
CY2023Q2 us-gaap Liabilities
Liabilities
63017000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
23000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
323142000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-279397000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
43768000
CY2023Q2 eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
56181000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
56181000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65760000
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.99
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10772000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
74792000
CY2023Q2 eldn Issuance Of Common Stock In Connection With Private Investment In Public Equity Transaction Net Of Issuance Costs Value
IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue
33017000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1720000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65760000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
43768000
us-gaap Net Income Loss
NetIncomeLoss
-76532000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
56181000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18145000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33791508
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25263692
CY2023Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
56181000
CY2023Q2 us-gaap Liabilities
Liabilities
63017000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
23000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
323142000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-279397000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
43768000
CY2023Q2 eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
56181000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
56181000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65760000
us-gaap Net Income Loss
NetIncomeLoss
-76532000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.74
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.99
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1381000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10772000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
74792000
CY2023Q2 eldn Issuance Of Common Stock In Connection With Private Investment In Public Equity Transaction Net Of Issuance Costs Value
IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue
33017000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1720000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65760000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
43768000
us-gaap Net Income Loss
NetIncomeLoss
-76532000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
56181000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18145000
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
43768000
CY2023Q2 eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
56181000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
56181000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65760000
us-gaap Net Income Loss
NetIncomeLoss
-76532000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.74
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.99
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
84183000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1381000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10772000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
74792000
CY2023Q2 eldn Issuance Of Common Stock In Connection With Private Investment In Public Equity Transaction Net Of Issuance Costs Value
IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue
33017000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1720000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65760000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
43768000
us-gaap Net Income Loss
NetIncomeLoss
-76532000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
56181000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18145000
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-098590-index-headers.html Edgar Link pending
0000950170-24-098590-index.html Edgar Link pending
0000950170-24-098590.txt Edgar Link pending
0000950170-24-098590-xbrl.zip Edgar Link pending
eldn-20240630.htm Edgar Link pending
eldn-20240630.xsd Edgar Link pending
eldn-ex31_1.htm Edgar Link pending
eldn-ex31_2.htm Edgar Link pending
eldn-ex32_1.htm Edgar Link pending
eldn-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
eldn-20240630_htm.xml Edgar Link completed
0000950170-24-098590-index-headers.html Edgar Link pending
0000950170-24-098590-index.html Edgar Link pending
0000950170-24-098590.txt Edgar Link pending
0000950170-24-098590-xbrl.zip Edgar Link pending
eldn-20240630.htm Edgar Link pending
eldn-20240630.xsd Edgar Link pending
eldn-ex31_1.htm Edgar Link pending
eldn-ex31_2.htm Edgar Link pending
eldn-ex32_1.htm Edgar Link pending
eldn-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
eldn-20240630_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending